Cyclacel Pharmaceuticals, Inc. (CYCC) financial statements (2021 and earlier)

Company profile

Business Address 200 CONNELL DRIVE
BERKELEY HEIGHTS, NJ 07922
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3323259121315
Cash and cash equivalents3323259121315
Prepaid expense    1  
Other current assets0001000
Other undisclosed current assets2322133
Total current assets:35262812141618
Noncurrent Assets
Operating lease, right-of-use asset111111 
Property, plant and equipment0000000
Other undisclosed noncurrent assets      1
Total noncurrent assets:1111111
TOTAL ASSETS:37272913151719
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2222223
Accounts payable1000111
Accrued liabilities2111211
Total current liabilities:2222223
Noncurrent Liabilities
Long-term debt and lease obligation111111 
Operating lease, liability111111 
Other undisclosed noncurrent liabilities      1
Total noncurrent liabilities:1111111
Total liabilities:4333434
Stockholders' equity
Stockholders' equity attributable to parent33242710121416
Common stock0000000
Additional paid in capital400389389370370370370
Accumulated other comprehensive loss(1)(1)(1)(1)(1)(1)(1)
Accumulated deficit(366)(363)(361)(359)(358)(355)(353)
Total stockholders' equity:33242710121416
TOTAL LIABILITIES AND EQUITY:37272913151719

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gross profit:    (0)  
Operating expenses(3)(3)(2)(2)(3)(2)(2)
Operating loss:(3)(3)(2)(2)(3)(2)(2)
Nonoperating income (expense)(0)001000
Investment income, nonoperating0000000
Foreign currency transaction gain (loss), before tax(0)(0)(0)0(0)00
Other nonoperating income 001000
Loss from continuing operations before income taxes:(3)(3)(2)(2)(3)(2)(2)
Income tax benefit0000000
Net loss attributable to parent:(3)(2)(2)(1)(2)(2)(2)
Preferred stock dividends and other adjustments(4)(0)(0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(7)(2)(2)(1)(2)(2)(2)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(3)(2)(2)(1)(2)(2)(2)
Comprehensive loss:(3)(2)(2)(1)(2)(2)(2)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent000(0)0(0)(0)
Comprehensive loss, net of tax, attributable to parent:(3)(2)(2)(1)(2)(2)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: